BACKGROUND: Melanoma comprises less than 3% of all cancers seen in children. Sentinel lymph node biopsy (SLNBX) is an important predictor of outcome in adult melanoma and has not been widely used in pediatrics. Furthermore, adjuvant interferon has only been rarely used in childhood high-risk disease. OBJECTIVE: To review our experience with high-risk melanoma, the feasibility of SLNBX and the tolerance of high-dose interferon (HDI) therapy. METHODS: We retrospectively reviewed the medical records of patients with the diagnosis of cutaneous melanoma at our center over a 10-year period. RESULTS: Eleven patients were identified (median age of 12 y). Six of 10 patients who underwent SLNBX had disease in the lymph nodes and no complications from this procedure were observed. After complete lymph node dissection in these 6 patients, 1 developed wound infection and 2 had chronic lymph edema. Five patients were treated with adjuvant HDI of whom 2 patients required dose modification due to myelosuppression and liver toxicity. After a median follow-up of 26 months, 10 out of 11 patients are in remission. CONCLUSIONS: SLNBX is feasible and safe in pediatric melanoma and offers the potential to identify patients at high risk for disease progression who could benefit from HDI.
BACKGROUND:Melanoma comprises less than 3% of all cancers seen in children. Sentinel lymph node biopsy (SLNBX) is an important predictor of outcome in adult melanoma and has not been widely used in pediatrics. Furthermore, adjuvant interferon has only been rarely used in childhood high-risk disease. OBJECTIVE: To review our experience with high-risk melanoma, the feasibility of SLNBX and the tolerance of high-dose interferon (HDI) therapy. METHODS: We retrospectively reviewed the medical records of patients with the diagnosis of cutaneous melanoma at our center over a 10-year period. RESULTS: Eleven patients were identified (median age of 12 y). Six of 10 patients who underwent SLNBX had disease in the lymph nodes and no complications from this procedure were observed. After complete lymph node dissection in these 6 patients, 1 developed wound infection and 2 had chronic lymph edema. Five patients were treated with adjuvant HDI of whom 2 patients required dose modification due to myelosuppression and liver toxicity. After a median follow-up of 26 months, 10 out of 11 patients are in remission. CONCLUSIONS: SLNBX is feasible and safe in pediatric melanoma and offers the potential to identify patients at high risk for disease progression who could benefit from HDI.
Authors: Lisa A Kottschade; Travis E Grotz; Roxana S Dronca; Diva R Salomao; Jose S Pulido; Nabil Wasif; James W Jakub; Sanjay P Bagaria; Riten Kumar; Judith S Kaur; Shane Y Morita; Steven L Moran; Jesse T Nguyen; Emily C Nguyen; Jennifer L Hand; Lori A Erickson; Jerry D Brewer; Christian L Baum; Robert C Miller; David L Swanson; Val Lowe; Svetomir N Markovic Journal: Am J Clin Oncol Date: 2014-12 Impact factor: 2.339
Authors: K T Huynh; Y Takei; C Kuo; R A Scolyer; R Murali; K Chong; L Takeshima; M-S Sim; D L Morton; R R Turner; J F Thompson; D S B Hoon Journal: Br J Dermatol Date: 2012-05-18 Impact factor: 9.302
Authors: Julia C Chisholm; Jozef Suvada; Ira J Dunkel; Michela Casanova; Weijiang Zhang; Natasha Ritchie; YounJeong Choi; Jane Park; Meghna Das Thakur; Stephen Simko; Nga Wan Rachel Tam; Andrea Ferrari Journal: Pediatr Blood Cancer Date: 2018-01-19 Impact factor: 3.167
Authors: Fariba Navid; Cynthia E Herzog; John Sandoval; Vinay M Daryani; Clinton F Stewart; Jami Gattuso; Belinda Mandrell; Sean Phipps; Wassim Chemaitilly; April Sykes; Andrew M Davidoff; Barry L Shulkin; Armita Bahrami; Wayne L Furman; Shenghua Mao; Jianrong Wu; Deborah Schiff; Bhaskar Rao; Alberto Pappo Journal: Pediatr Blood Cancer Date: 2016-04-01 Impact factor: 3.167